118 related articles for article (PubMed ID: 32518840)
41. Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups.
Brindle P; May M; Gill P; Cappuccio F; D'Agostino R; Fischbacher C; Ebrahim S
Heart; 2006 Nov; 92(11):1595-602. PubMed ID: 16762981
[TBL] [Abstract][Full Text] [Related]
42. External validation of two Framingham cardiovascular risk equations and the Pooled Cohort equations: A nationwide registry analysis.
Wallisch C; Heinze G; Rinner C; Mundigler G; Winkelmayer WC; Dunkler D
Int J Cardiol; 2019 May; 283():165-170. PubMed ID: 30429082
[TBL] [Abstract][Full Text] [Related]
43. Improving diabetes care: multi-component cardiovascular disease risk reduction strategies for people with diabetes in South Asia--the CARRS multi-center translation trial.
; Shah S; Singh K; Ali MK; Mohan V; Kadir MM; Unnikrishnan AG; Sahay RK; Varthakavi P; Dharmalingam M; Viswanathan V; Masood Q; Bantwal G; Khadgawat R; Desai A; Sethi BK; Shivashankar R; Ajay VS; Reddy KS; Narayan KM; Prabhakaran D; Tandon N
Diabetes Res Clin Pract; 2012 Nov; 98(2):285-94. PubMed ID: 23084280
[TBL] [Abstract][Full Text] [Related]
44. A comparison of laboratory-based and office-based Framingham risk scores to predict 10-year risk of cardiovascular diseases: a population-based study.
Dehghan A; Ahmadnia Motlagh S; Khezri R; Rezaei F; Aune D
J Transl Med; 2023 Oct; 21(1):687. PubMed ID: 37789412
[TBL] [Abstract][Full Text] [Related]
45. Ambiguity about Selection of Cardiovascular Risk Stratification Tools: Evidence from a North Indian Rural Population.
Singh T; Pilania M; Jat GS; Kumar R
Indian J Community Med; 2018; 43(3):170-174. PubMed ID: 30294082
[TBL] [Abstract][Full Text] [Related]
46. Validation of the Framingham general cardiovascular risk score in a multiethnic Asian population: a retrospective cohort study.
Chia YC; Gray SY; Ching SM; Lim HM; Chinna K
BMJ Open; 2015 May; 5(5):e007324. PubMed ID: 25991451
[TBL] [Abstract][Full Text] [Related]
47. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys.
Hajifathalian K; Ueda P; Lu Y; Woodward M; Ahmadvand A; Aguilar-Salinas CA; Azizi F; Cifkova R; Di Cesare M; Eriksen L; Farzadfar F; Ikeda N; Khalili D; Khang YH; Lanska V; León-Muñoz L; Magliano D; Msyamboza KP; Oh K; Rodríguez-Artalejo F; Rojas-Martinez R; Shaw JE; Stevens GA; Tolstrup J; Zhou B; Salomon JA; Ezzati M; Danaei G
Lancet Diabetes Endocrinol; 2015 May; 3(5):339-55. PubMed ID: 25819778
[TBL] [Abstract][Full Text] [Related]
48. Performance of the Framingham risk models and pooled cohort equations for predicting 10-year risk of cardiovascular disease: a systematic review and meta-analysis.
Damen JA; Pajouheshnia R; Heus P; Moons KGM; Reitsma JB; Scholten RJPM; Hooft L; Debray TPA
BMC Med; 2019 Jun; 17(1):109. PubMed ID: 31189462
[TBL] [Abstract][Full Text] [Related]
49. Cardiovascular Risk Factor Knowledge and Behaviors Among Low-Income Urban Women in Mysore, India.
Krupp K; Wilcox ML; Srinivas A; Srinivas V; Madhivanan P; Bastida E
J Cardiovasc Nurs; 2020; 35(6):588-598. PubMed ID: 32084082
[TBL] [Abstract][Full Text] [Related]
50. Performance of a Framingham cardiovascular risk model among Indians and Europeans in New Zealand and the role of body mass index and social deprivation.
Rabanal KS; Meyer HE; Pylypchuk R; Mehta S; Selmer RM; Jackson RT
Open Heart; 2018; 5(2):e000821. PubMed ID: 30018780
[TBL] [Abstract][Full Text] [Related]
51. A new selection method to increase the health benefits of CVD prevention strategies.
Lagerweij GR; de Wit GA; Moons KG; van der Schouw YT; Verschuren WM; Dorresteijn JA; Koffijberg H;
Eur J Prev Cardiol; 2018 Apr; 25(6):642-650. PubMed ID: 29411690
[TBL] [Abstract][Full Text] [Related]
52. Implications of the US cholesterol guidelines on eligibility for statin therapy in the community: comparison of observed and predicted risks in the Framingham Heart Study Offspring Cohort.
Andersson C; Enserro D; Larson MG; Xanthakis V; Vasan RS
J Am Heart Assoc; 2015 Apr; 4(4):. PubMed ID: 25888372
[TBL] [Abstract][Full Text] [Related]
53. SCORE should be preferred to Framingham to predict cardiovascular death in French population.
Marchant I; Boissel JP; Kassaï B; Bejan T; Massol J; Vidal C; Amsallem E; Naudin F; Galan P; Czernichow S; Nony P; Gueyffier F
Eur J Cardiovasc Prev Rehabil; 2009 Oct; 16(5):609-15. PubMed ID: 20054289
[TBL] [Abstract][Full Text] [Related]
54. Does Adding Adverse Pregnancy Outcomes Improve the Framingham Cardiovascular Risk Score in Women? Data from the Tehran Lipid and Glucose Study.
Saei Ghare Naz M; Sheidaei A; Aflatounian A; Azizi F; Ramezani Tehrani F
J Am Heart Assoc; 2022 Jan; 11(2):e022349. PubMed ID: 35016530
[TBL] [Abstract][Full Text] [Related]
55. Comparison of Nonblood-Based and Blood-Based Total CV Risk Scores in Global Populations.
Gaziano TA; Abrahams-Gessel S; Alam S; Alam D; Ali M; Bloomfield G; Carrillo-Larco RM; Dorairaj P; Gutierrez L; Irazola V; Levitt NS; Miranda JJ; Bernabe-Ortiz A; Pandya A; Rubinstein A; Steyn K; Xavier D; Yan LL
Glob Heart; 2016 Mar; 11(1):37-46.e2. PubMed ID: 27102021
[TBL] [Abstract][Full Text] [Related]
56. Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with Type 2 diabetes mellitus.
Metcalf PA; Wells S; Scragg RK; Jackson R
N Z Med J; 2008 Sep; 121(1281):49-57. PubMed ID: 18797484
[TBL] [Abstract][Full Text] [Related]
57. Cardiovascular risk prediction: a comparative study of Framingham and quantum neural network based approach.
Narain R; Saxena S; Goyal AK
Patient Prefer Adherence; 2016; 10():1259-70. PubMed ID: 27486312
[TBL] [Abstract][Full Text] [Related]
58. Cost-effectiveness of the non-laboratory based Framingham algorithm in primary prevention of cardiovascular disease: A simulated analysis of a cohort of African American adults.
Kariuki JK; Gona P; Leveille SG; Stuart-Shor EM; Hayman LL; Cromwell J
Prev Med; 2018 Jun; 111():415-422. PubMed ID: 29224996
[TBL] [Abstract][Full Text] [Related]
59. Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort.
Simmons RK; Coleman RL; Price HC; Holman RR; Khaw KT; Wareham NJ; Griffin SJ
Diabetes Care; 2009 Apr; 32(4):708-13. PubMed ID: 19114615
[TBL] [Abstract][Full Text] [Related]
60. Who needs laboratories and who needs statins?: comparative and cost-effectiveness analyses of non-laboratory-based, laboratory-based, and staged primary cardiovascular disease screening guidelines.
Pandya A; Weinstein MC; Salomon JA; Cutler D; Gaziano TA
Circ Cardiovasc Qual Outcomes; 2014 Jan; 7(1):25-32. PubMed ID: 24425701
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
